Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial

BACKGROUND AND AIMS: Ulcerative colitis [UC] impacts patients’ health-related quality of life [HRQoL]. We assessed HRQoL and an exploratory patient-level composite endpoint (‘Comprehensive Disease Control’ [CDC]) in individuals receiving filgotinib [an oral JAK1 preferential inhibitor] in the SELECT...

Descripción completa

Detalles Bibliográficos
Autores principales: Schreiber, Stefan, Feagan, Brian G, Peyrin-Biroulet, Laurent, Vermeire, Séverine, Faes, Margaux, Harris, Kristina, Oortwijn, Alessandra, Daniele, Patrick, Patel, Haridarshan, Danese, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274306/
https://www.ncbi.nlm.nih.gov/pubmed/36756874
http://dx.doi.org/10.1093/ecco-jcc/jjad018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274306/
https://www.ncbi.nlm.nih.gov/pubmed/36756874
http://dx.doi.org/10.1093/ecco-jcc/jjad018

Ejemplares similares